The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | T-cell engaging antibodies: what lessons have we learnt?
The use of T-cell engaging antibodies for acute myeloid leukemia (AML) treatment is in the very early stages. In this interview, Marion Subklewe, MD, of the University of Munich, Munich, Germany, highlights the importance of examining the T-cell engaging antibody constructs that are currently being used for acute lymphoblastic leukemia treatment and applying the lessons learnt in this setting to AML. This interview was recorded at the International Conference on Acute Myeloid Leukemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
